Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these compounds enhance insulin secretion and reduc

The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing contrasts in their ph